RT Journal Article
SR Electronic
T1 Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.10.21255127
DO 10.1101/2021.04.10.21255127
A1 Norbury, Agnes
A1 Rutter, Sarah B.
A1 Collins, Abigail B.
A1 Costi, Sara
A1 Jha, Manish K.
A1 Horn, Sarah R.
A1 Kautz, Marin
A1 Corniquel, Morgan
A1 Collins, Katherine A.
A1 Glasgow, Andrew M.
A1 Brallier, Jess
A1 Shin, Lisa M.
A1 Charney, Dennis S.
A1 Murrough, James W.
A1 Feder, Adriana
YR 2021
UL http://medrxiv.org/content/early/2021/04/14/2021.04.10.21255127.abstract
AB Promising initial data indicate that the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine may be beneficial in post-traumatic stress disorder (PTSD). Here, we explore the neural correlates of ketamine-related changes in PTSD symptoms, using a rich battery of functional imaging data (two emotion-processing tasks and one task-free scan), collected from a subset of participants of a randomized clinical trial of repeated-dose intravenous ketamine vs midazolam (total N=21). In a pre-registered analysis, we tested whether changes in an a priori set of imaging measures were predictive of improvement in PTSD symptoms, using leave-one-out cross-validated elastic-net regression models. Improvements in PTSD severity were associated with increased functional connectivity between the ventromedial prefrontal cortex (vmPFC) and amygdala during emotional face-viewing (change score retained in model with minimum predictive error in left-out subjects, standardized regression coefficient [β]=2.90). This effect was stronger in participants who received ketamine compared to midazolam (interaction β=0.86), and persisted following inclusion of concomitant change in depressive symptoms in the analysis model (β=0.69). Improvement following ketamine was also predicted by decreased dorsal anterior cingulate activity during emotional conflict regulation, and increased task-free connectivity between the vmPFC and anterior insula (βs=-2.82, 0.60). Exploratory follow-up analysis via dynamic causal modelling revealed that whilst improvement in PTSD symptoms following either drug was associated with decreased excitatory modulation of amygdala→vmPFC connectivity during emotional face-viewing, increased top-down inhibition of the amygdala by the vmPFC was only observed in participants who improved under ketamine. Individuals with low prefrontal inhibition of amygdala responses to faces at baseline also showed greater improvements following ketamine treatment. These preliminary findings suggest that, specifically under ketamine, improvements in PTSD symptoms are accompanied by normalization of hypofrontal control over amygdala responses to social signals of threat.Competing Interest StatementDrs. Feder and Charney are named co-inventors on a patent application in the US, and several issued patents outside the US, filed by the Icahn School of Medicine at Mount Sinai (ISMMS) related to the use of ketamine for the treatment of PTSD. This intellectual property has not been licensed. Dr. Jha has received contract research grants from Acadia Pharmaceuticals and Janssen Research & Development, educational grant to serve as Section Editor of the Psychiatry & Behavioral Health Learning Network, consultant fees from Eleusis Therapeutics US, Inc, and honoraria for CME presentations from North American Center for Continuing Medical Education and Global Medical Education. Dr. K. Collins is a paid independent rater for Medavante-Prophase. In the past 5 years, Dr. Murrough has provided consultation services and/or served on advisory boards for Allergan, Boehreinger Ingelheim, Clexio Biosciences, Fortress Biotech, FSV7, Global Medical Education (GME), Novartis, Otsuka, Sage Therapeutics, and Engrail Therapeutics. Dr. Murrough is named on a patent pending for neuropeptide Y as a treatment for mood and anxiety disorders and on a patent pending for the use of KCNQ channel openers to treat depression and related conditions. The ISMMS (employer of Dr. Murrough) is named on a patent and has entered into a licensing agreement and will receive payments related to the use of ketamine or esketamine for the treatment of depression. The ISMMS Medicine is also named on a patent related to the use of ketamine for the treatment of PTSD. Dr. Murrough is not named on these patents and will not receive any payments. Dr. Charney is named as co-inventor on patents filed by the ISMMS relating to the treatment for treatment-resistant depression, suicidal ideation and other disorders. ISMMS has entered into a licensing agreement with Janssen Pharmaceuticals, Inc. and it has and will receive payments from Janssen under the license agreement related to these patents for the treatment of treatment-resistant depression and suicidal ideation. Consistent with the ISMMS Faculty Handbook (the medical school policy), Dr. Charney is entitled to a portion of the payments received by the ISMMS. Since SPRAVATO has received regulatory approval for treatment-resistant depression, ISMMS and thus, through the ISMMS, Dr. Charney, will be entitled to additional payments, beyond those already received, under the license agreement. Dr. Charney is a named co-inventor on several patents filed by ISMMS for a cognitive training intervention to treat depression and related psychiatric disorders. The ISMMS has entered into a licensing agreement with Click Therapeutics, Inc. and has and will receive payments related to the use of this cognitive training intervention for the treatment of psychiatric disorders. In accordance with the ISMMS Faculty Handbook, Dr. Charney has received a portion of these payments and is entitled to a portion of any additional payments that the medical school might receive from this license with Click Therapeutics. Dr. Charney is a named co-inventor on a patent application filed by the ISMMS for the use of intranasally administered Neuropeptide Y (NPY) for the treatment of mood and anxiety disorders. This intellectual property has not been licensed. The other authors declare no conflicts of interest.Clinical TrialNCT02397889Clinical Protocols https://osf.io/8bewv/ Funding StatementThis work was supported by an Independent Investigator Award from the Brain and Behavior Research Foundation to AF (grant number 23144), Technology Development Awards from Mount Sinai Innovation Partners and the Mount Sinai i3 Accelerator, and a donation from Mr. Gerald Greenwald and Mrs. Glenda Greenwald. Additional funding was provided by the Ehrenkranz Laboratory for Human Resilience, a component of the Depression and Anxiety Center for Discovery and Treatment at Icahn School of Medicine at Mount Sinai.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethical approval from the Institutional Review Board at the Icahn School of Medicine at Mount Sinai.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData associated with this manuscript is not currently publicly available, as permission for public sharing was not sought at the time of participant consent.